SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The 4G/4G PAI-1 genotype was significantly associated with a high prevalence of arterial hypertension.
|
17351368 |
2007 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Stroke prevalence and odds ratio (OR) were assessed for the following parameters: G20210A prothrombin, Arg506Glu factor V Leiden, C677T MTHFR, and 4G/5G PAI-1 polymorphisms; total number of study polymorphisms in a particular subject (genetic sum); and classic vascular risk factors of hypertension, obesity, diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertriglyceridemia, and elevated levels of low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein cholesterol.
|
24189452 |
2014 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.
|
15194475 |
2004 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
Addition of waist circumference to the models either decreased or nullified the contribution of PAI-1act to BP and hypertension development.
|
31356402 |
2019 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
These results demonstrates that hypertension and insulin resistance induced by COC is associated with increased cardiac RAS and PAI-1 gene expression, which is likely to be through corticosterone-dependent but not aldosterone-dependent mechanism.
|
26934364 |
2017 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
Multivariate logistic regression analysis showed that PAI-1 4G/4G (P = 0.01) and the prevalence of hypertension (P < 0.0001) are independent risk factors of development of type 2 diabetic nephropathy.
|
10652041 |
2000 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
When stratified according to PAI-1 4G/5G polymorphism, there was no significant difference in all metabolic parameters among PAI-1 genotype groups in patients with HTN as well as subjects with normal blood pressure.
|
22613596 |
2012 |
SERPINE1
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Patients with metabolic syndrome were characterized with increased body mass index (BMI), waist circumference, and HOMA-IR and HOMA-beta levels, and all had increased blood pressure and triglyceride levels, low high-density lipoprotein cholesterol levels, increased PAI-1 levels and reduced antioxidative defense levels.
|
17848118 |
2007 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The most significant result among all univariate and multivariate tests performed in this study was the heterogeneity of correlation between PAI-1 and mean arterial pressure at rs10738554, near SLC24A2, a gene previously associated with high blood pressure in African Americans.
|
28408189 |
2017 |
SERPINE1
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The present study showed that the 4G/4G genotype was associated with elevated plasma PAI-1 activity in Chinese patients with and without hypertension.
|
12670745 |
2003 |
SERPINE1
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The presence of type 2 diabetes associated with 3.2-fold increased PAI-1 expression (adjusted p=0.033), while the presence of hypertension associated with about 50% reduction of IL-8 and TIMP-1.
|
25496999 |
2015 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The functional plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism has previously been associated with hypertension.
|
21490692 |
2011 |
SERPINE1
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Hypertension is associated with increased expression of FABP3, FAS, FN1, IL1R2, LPL, SERPINE1, TGFB1, and VCAM1 and decreased expression of SELPLG and SERPINEB2.
|
23337395 |
2014 |
SERPINE1
|
0.600 |
AlteredExpression
|
group |
BEFREE |
At multivariate analysis, only hyperhomocysteinemia (OR 11, 95% CI 3.6-36.2; p < 0.0001) and elevated PAI-1 levels (OR 8.9, 95% CI 3.5-41.3; p < 0.01), in addition to hypertension (OR 40.5, 95% CI 8.6-188.8; p < 0.00001) and hypercholesterolemia (OR 3.1, 95% CI 1.6-20.5; p < 0.05), were independent risk factors for CRVO.
|
11583306 |
2001 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
We observed significantly lower concentration of PAI-1:Ag in DF patients treated for hypertension as compared to patients without hypertension.
|
28193577 |
2017 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
We compared concentrations of 4 different biomarkers (urinary albumin:creatinine ratio, circulating C-reactive protein, aldosterone:renin ratio, and plasminogen activator inhibitor-1) in nonhypertensive Framingham offspring study participants with none (n=233), 1 (n=474), or both (n=322) parents with hypertension.
|
18574071 |
2008 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Hypertension (odds ratio [OR] = 1.953, p = 0.020), tHcy (OR = 1.059, p = 0.029), thyroid-stimulating hormone (OR = 0.876, p = 0.039), and the PAI-1 genotype dominant allele model (OR = 1.748, p = 0.047) were associated with IS by multivariate analysis.
|
30160528 |
2018 |
SERPINE1
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Its effects on ROS production, AP-1 activity, plasminogen activator inhibitor 1 (PAI-1) gene expression, and cellular proliferation and migration were measured in response to high glucose and angiotensin II (Ang II) concentrations, two major factors in the pathogenesis of atherosclerosis in patients with diabetes and hypertension.
|
15827742 |
2005 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
Considering cardiovascular diseases there is a number of genes involved in lipid metabolism (apolipoproteins, lipoprotein receptors, lipolytic enzymes), thrombosis/hemostasis (platelet receptors, pro- and anticoagulant proteins, fibrinogen, PAI's), hypertension (angiotensin converting enzyme, angiotensinogen) glucose metabolism (glucose transporters, enzymes) and obesity (hormones, receptors), that are interesting candidates for sophisticated genetic risk assessment.
|
9654602 |
1998 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The aims of this study were to observe associations of the genetic polymorphism for PAI-1 and t-PA with hypertension and atherothrombotic stroke, and to elucidate whether impaired fibrinolytic activity in atherothrombotic stroke was related to atherothrombosis per se or to other risk factors such as hypertension.
|
11385207 |
2001 |
SERPINE1
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Furthermore, increased plasma PAI-1 levels are associated with dyslipidemia, hyperinsulinemia and hypertension.
|
10867719 |
2000 |
SERPINE1
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In conclusion, the results indicated that the I/D polymorphism of the ACE gene was not related to plasma PAI-1 levels in a Chinese population with hypertension.
|
9524054 |
1998 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
Post-phlebotomy, PRA and PAI-1 responses were more dramatic, but the NO response less in normotensive subjects having a parental history of hypertension, suggesting that these changes may represent familial, possibly genetic influences before overt hypertension occurs.
|
19154322 |
2008 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The T94G genotypes and plasma levels of adiponectin, and PAI-1 were determined in 568 Chinese patients, 212 with and 356 without hypertension, to study the possible associations of T94G genotype, plasma adiponectin, PAI-1 and blood pressure.
|
16741355 |
2007 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
Although Angiotensin II-induced hypertension was blunted in PAI-1<sup>-/-</sup> mice, cardiac hypertrophy was accelerated.
|
28588076 |
2017 |